A Clinical Trial to Develop a Peritoneal Carcinomatosis Index (PCI) in Ovarian
N/A
N/A
Female
Ovarian Cancer
Trial Information
A Clinical Trial to Develop a Peritoneal Carcinomatosis Index (PCI) in Ovarian
Patients with primary ovarian cancer
- Informed consent
- Digital photography & Checking PCI (tumor size, number, and Characteristics)
- Postoperative surveillance(tumor marker, image and physical examination)
1. Developing the best fitting PCI model to reflect recurrence-free survival and
overall survival
- Selection of items
- Weighting by items and tumor characteristics
2. Analysis of prognostic impact of PCI compared to conventional staging system (FIGO
stage) for ovarian cancer
Inclusion Criteria:
1. Preoperative clinical diagnosis of ovarian cancer, tubal cancer, and primary
peritoneal carcinoma (all stage)
2. Available preoperative image study (CT and/or MRI and/or PET)
3. Patients who gave a written informed consent
4. Patients must be surgical candidate considering medical and psychological condition
Exclusion Criteria:
- Patients who refuse to participate or want to withdraw at anytime.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Devleopment for the peritoneal carcinomatosis index (PCI)
Outcome Time Frame:
55 months
Safety Issue:
No
Authority:
Korea: Institutional Review Board
Study ID:
NCCCTS-08-309
NCT ID:
NCT01538498
Start Date:
April 2008
Completion Date:
February 2013
Related Keywords:
- Ovarian Cancer
- PCI
- Ovarian cancer
- Ovarian Neoplasms
- Carcinoma
Name | Location |
|---|
